PF-04217903是ATP竞争性c-Met抑制剂,IC50为4.8 nM,对突变型Y1230C无活性。
PF-04217903 is an orally active, potent and ATP-competitive c-Met inhibitor with IC50 of 4.8 nM.
1% DMSO+30% polyethylene glycol+1% Tween 80
~2 μM
45 mg/kg 口服处理
动物 A (mg/kg) = 动物 B (mg/kg)×动物 B的Km系数/动物 A的Km系数 | |
例如,已知某工具药用于小鼠的剂量为88 mg/kg , 则用于大鼠的剂量换算方法:将88 mg/kg 乘以小鼠的Km系数(3),再除以大鼠的Km系数(6),得到该药物用于大鼠的等效剂量44 mg/kg。
[1] Timofeevski SL, et al. Biochemistry, 2009, 48(23), 5339-5349.
[2] Shojaei F, et al. HGF/c-Met acts as an alternative angiogenic pathway in sunitinib-resistant tumors. Cancer Res, 2010, 70(24), 10090-10100.
[3] Krumbach R, et al. Primary resistance to cetuximab in a panel of patient-derived tumour xenograft models: activation of MET as one mechanism for drug resistance. Eur J Cancer, 2011, 47(8), 1231-1243.
分子式 C19H16N8O |
分子量 372.38 |
CAS号 956905-27-4 |
储存方式 ﹣20 ℃冷藏长期储存。冰袋运输 |
溶剂(常温) |
DMSO 5 mg/mL |
Water <1 mg/mL |
Ethanol <1 mg/mL |
体内溶解度
NCT Number | Conditions | Interventions | Sponsor/Collaborators | Phases | Start Date | Last Updated |
NCT00706355 | Neoplasms | Drug: PF-04217903 | Pfizer | Phase 1 | 2008-08-01 | 2012-06-15 |
注:以上所有数据均来自公开文献,并不保证对所有实验均有效,数据仅供参考。
相关化合物库
使用AMQUAR产品发表文献后请联系我们